Antimicrobial Susceptibility Testing Market is Projected to Reach USD 4.7 billion by 2027

Antimicrobial susceptibility testing (AST) is a type of laboratory testing used to determine the effectiveness of antibiotics or antimicrobial agents against a particular bacterial or fungal strain. This type of testing is essential in the diagnosis and treatment of infectious diseases, as it helps clinicians determine the most appropriate antimicrobial therapy for their patients.

The global Antimicrobial Susceptibility Testing Market is expected to grow at a significant rate in the coming years. Factors driving this growth include the increasing prevalence of infectious diseases, the rise of antimicrobial resistance, and the growing demand for rapid and accurate diagnostic tests.

The market is segmented based on the type of testing method, including phenotypic and genotypic testing. Phenotypic testing is the most commonly used method and includes techniques such as disk diffusion, broth microdilution, and gradient diffusion. Genotypic testing, on the other hand, involves the analysis of genetic material to determine the presence of antimicrobial resistance genes.

Geographically, North America is currently the largest market for antimicrobial susceptibility testing, followed by Europe and Asia Pacific. However, the Asia Pacific region is expected to grow at the highest rate due to the increasing prevalence of infectious diseases and the growing demand for diagnostic tests in the region.

The prominent player in Antimicrobial susceptibility testing are bio Mérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US) among others. These companies are investing in research and development activities to develop advanced diagnostic tests and expand their product portfolios to stay competitive in the market.

Direct Purchase at https://www.reportsnreports.com/purchase.aspx?name=1308641